Search research articles
Contact Us
Filters
Showing results (211-220 of 255) with videos related to
Page
of 26
Sort By:
Journal of Neuro-Oncology
|
May 24, 2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)
Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Journal of Neuro-Oncology
|
February 24, 2001
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma
S V Rajkumar, J M Reid, P J Novotny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2010
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
Jann N Sarkaria, Eva Galanis, Wenting Wu, et al.
Molecular Phylogenetics and Evolution
|
March 17, 2018
A phylogenomic perspective on the robust capuchin monkey (Sapajus) radiation: First evidence for extensive population admixture across South America
Marcela G M Lima, José de Sousa E Silva-Júnior, David Černý, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 6, 2004
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial
Paul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Neuro-Oncology
|
February 1, 2020
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma
William G Breen, S Keith Anderson, Xiomara W Carrero, et al.
Cancer
|
January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Journal of Virology
|
May 18, 2001
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
S W Barnett, S Lu, I Srivastava, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 255) with videos related to
Sort By:
Page
of 26
Journal of Neuro-Oncology
|
May 24, 2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)
Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Journal of Neuro-Oncology
|
February 24, 2001
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma
S V Rajkumar, J M Reid, P J Novotny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2010
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
Jann N Sarkaria, Eva Galanis, Wenting Wu, et al.
Molecular Phylogenetics and Evolution
|
March 17, 2018
A phylogenomic perspective on the robust capuchin monkey (Sapajus) radiation: First evidence for extensive population admixture across South America
Marcela G M Lima, José de Sousa E Silva-Júnior, David Černý, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 6, 2004
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial
Paul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Neuro-Oncology
|
February 1, 2020
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma
William G Breen, S Keith Anderson, Xiomara W Carrero, et al.
Cancer
|
January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Journal of Virology
|
May 18, 2001
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
S W Barnett, S Lu, I Srivastava, et al.
Page
of 26